China, Shanghai
Li Ping
Shanghai Tongji Hospital has performed 1,500+ CAR-T cell infusions since 2014, making it a leading center for cellular immunotherapy. The hematology team reports an 87.5% complete remission rate at three months for lymphoma patients. They specialize in treating high-risk and refractory cases using advanced CAR-T and CAR-NK therapies. Every case goes before a multidisciplinary tumor board including specialists in radiology and pathology. This university-affiliated hospital also offers epigenetic immunotherapy for patients who have not responded to previous treatments.